Eli Lilly & Co. (LLY) May weekly 737 straddle into quarter results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/27/2026
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices slide about 2% as US, Iran explore path out of war
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Eli Lilly (LLY) PT Raised to $1,001 at BMO Capital
April 30, 2024 4:50 PM EDTBMO Capital analyst Evan David Seigerman raised the price target on Eli Lilly (NYSE: LLY) to $1,001.00 (from $900.00) while maintaining a Outperform rating.
The analyst comments "A high-quality earnings miss is one that 1) characterizes unprecedented demand; 2) justifies performance miss with supply constraints; 3) highlights efforts... More
Eli Lilly (LLY) PT Raised to $885 at Cantor Fitzgerald
April 30, 2024 2:01 PM EDTCantor Fitzgerald analyst Louise Chen raised the price target on Eli Lilly (NYSE: LLY) to $885.00 (from $815.00) while maintaining a Overweight rating.
The analyst comments "For 1Q24, US Zepbound revenue was $517MM vs. $363MM for FactSet. Zepbound is already annualizing at over... More
